JAK/STAT and AP1 function in cancer development

The research group of LK consists currently of  several students, and two biomedical scientists financed through the LBI-CR, MUW, VETMED and third party grants. The team is focused on transgenic mouse research and the analysis of tumour models as well as human patients tumor samples. Lukas Kenner (LK) is group leader at the Ludwig Boltzmann Institute for Cancer Research focusing on molecular aspects of prostate cancer and supervises a separate research group at the Institute of Clinical Pathology, Universitiy Hospital Vienna (AKH).


The group of LK formed in 2006 and LK supervises several national and international research projects. Together with our partner Company TissueGnostics™ LK and Biomedical Scientist Michaela Schlederer developed and improved software for protein quantification stained by immunohistochemical or immunofluorescence techniques from tissue slides.One focus of his group is the role of JunB for Lymphoma development, which is partly funded by the FWF and the “Fellinger” Fonds. Further grant money was attracted through international collaboration with groups in Italy and France (www.novussanguis.org) focusing on translational work with mesenchymal stem cells (MSCs). In addition, LK was part of the GenAU (Genome Austria) Inflammobiota project) which focuses on the role of Jak/Stat pathway in Inflammatory Bowel Disease (IBD). At the LBI-CR, LK investigates the role of Jak/Stat pathway in prostate cancer development.


Visit Kenner lab at LBI for Cancer Research


Selected publications


  • Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736. IF 10.7Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature medicine 2012;18:1699-704. IF: 28.0

  • Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2010;107:16228-33. IF: 9.8

  • Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 2010;138:1003-11 e1-5. IF: 13.9

Lukas Kenner, MD

Professor for Pathology of Laboratory Animals

Medical University of Vienna

Ludwig Boltzmann Institute for Cancer Research


Cytokines and JAK/STAT signaling in cancer

Interleukin-6/JAK/STAT signaling controls prostate cancer development and metastasis. Our findings open new avenues to therapy by modulating IL6/JAK/STAT signaling in prostate cancer patients. 

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at

Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at